Clinical trials: Carcinomas
Carcinoma, Non-Small-Cell Lung, Adenocarcinoma
Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146)
The main objective of this study is to investigate whether administration of maintenance temozolomide following standard treatment could possibly prevent or delay the onset of brain metastases in patients with controlled…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Adenocarcinoma, Carcinoma, Large Cell, Carcinoma, Squamous Cell
- Trial name
- NCT00632203
- Testing
- Temozolomide
- Volunteers
- 53 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Midline
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers
This study is divided into two parts; Part 1 of the study is a dose escalation phase to select the recommended dose for Part 2 based on the safety, pharmacokinetic, and pharmacodynamic profiles observed after oral administration…
- Trial name
- NCT01587703
- Testing
- GSK525762
- Where
- 17 sites in United States, Australia and 5 more
- Volunteers
- 196 people
- Sponsor
- GlaxoSmithKline
Advanced Solid Tumor, Lung Squamous Cell Carcinoma
JMT106 Injection in the Treatment of Advanced Solid Tumors
This study is the first-in-human Phase I study of JMT106 injection, comprising two phases: Dose escalation with backfill and cohort expansion. The planned study population consists of subjects with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Lung Squamous Cell Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT07275073
- Testing
- JMT106 Injection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai JMT-Bio Inc.
Small Cell Lung Carcinoma
A Phase IIII Study of AL8326 in Small Cell Lung Cancer
This is a multicenter, randomized, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of AL8326 tablets in small cell lung cancer (SCLC) patients with disease progression or recurrence after…
- Trial name
- NCT06247605
- Testing
- AL8326 tablets
- Where
- China
- Volunteers
- 243 people
- Sponsor
- Advenchen Laboratories Nanjing Ltd.
Non-Small Cell Lung Cancer
A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer
This study evaluated the efficacy and safety of tislelizumab in combination with platinum (cisplatin or carboplatin) and pemetrexed compared with platinum and pemetrexed alone as first-line treatment in participants with Stage…
- Trial name
- NCT03663205
- Testing
- Tislelizumab, Cisplatin, Carboplatin
- Where
- 47 sites in China
- Volunteers
- 334 people
- Sponsor
- BeiGene
Non-Small-Cell Lung Cancer
Phase II Study in Patients With Recurrent Non-Small-Cell Lung Cancer
Determine tumor response rate and time to disease progression, survival and safety in total populations.
- Trial name
- NCT00063388
- Testing
- Cetuximab
- Where
- 8 sites in United States
- Volunteers
- 66 people
- Sponsor
- Eli Lilly and Company
Squamous Cell Carcinoma of the Skin, Malignant Melanoma of Skin
Intratumoral PH-762 for Cutaneous Carcinoma
The goal of this clinical trial is to evaluate the safety and tolerability of intratumoral injections of PH-762 in squamous cell carcinoma, melanoma, or Merkel cell carcinomas of the skin, to understand what the body does to the…
- Conditions
- Squamous Cell Carcinoma of the Skin, Malignant Melanoma of Skin, Merkel Cell Carcinoma of Skin
- Trial name
- NCT06014086
- Testing
- PH-762
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Phio Pharmaceuticals Inc.
Esophageal Squamous Cell Carcinoma
KN046 in Subjects With Late Stage Esophageal Squamous Cell Carcinoma
This is an open-label, multi-center, single arm study to evaluate the efficacy, safety and tolerability of KN046 in subjects with advanced unresectable or metastatic esophageal squamous cell carcinoma (ESCC).
- Trial name
- NCT03925870
- Testing
- KN046
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Gastric Cancer, Renal Cell Carcinoma
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
The purpose of this study is to test the safety and tolerability of HFB200301 as a single agent and in combination with tislelizumab in patients with advanced cancers. There are two parts in this study.
- Conditions
- Gastric Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma
- Trial name
- NCT05238883
- Testing
- HFB200301, Tislelizumab
- Where
- 10 sites in United States, Spain
- Volunteers
- 72 people
- Sponsor
- HiFiBiO Therapeutics
Carcinoma, Non-Small-Cell Lung
Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer
The study will enroll approximately 33 EGFr positive chemotherapy-naive stage IV non-small cell lung cancer patients. Patients will receive cetuximab in combination with carboplatin and paclitaxel for two cycles or until disease…
- Trial name
- NCT00034541
- Testing
- cetuximab, paclitaxel, carboplatin
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Eli Lilly and Company
Hepatocellular Carcinoma
Immunotherapy for Advanced Liver Cancer
This is a randomized, controlled multi-site, multi-national clinical trial conducted in Thailand and Malaysia for Asian adults (males or females), 18 years of age and older presenting with advanced HCC (BCLC stage C) including…
- Trial name
- ALIVE (NCT05033522)
- Testing
- AlloStim® immunotherapy, FOLFOX regimen, Sorafenib
- Where
- 8 sites in Malaysia, Thailand
- Volunteers
- 150 people
- Sponsor
- Mirror Biologics, Inc.
Gastric Carcinoma
Dose Escalation Study of Liposomal Paclitaxel With/Without Capecitabine in Patients With Advanced Gastric Carcinoma
The purpose of this study is to investigate the maximum tolerated dose and pharmacokinetics of liposomal paclitaxel with/without capecitabine in Chinese cancer patients with advanced gastric carcinoma.
- Trial name
- NCT00639522
- Testing
- Liposomal paclitaxel and capecitabine
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Nanjing Sike Pharmaceutical Co., Ltd.
Multiple Sclerosis
Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study
The planned study will be a prospective, non-interventional, observational cohort study using the structure of a registry. Medication usage behavior will be observed for 6 months, while documentation behavior on the wellness…
- Trial name
- PROmyBETAapp (NCT03134573)
- Testing
- Interferon beta-1b (Betaferon, BAY86-5046), Betaconnect auto-injector, myBETAapp
- Where
- Germany
- Volunteers
- 96 people
- Sponsor
- Bayer
Hepatocellular Carcinoma
PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma
This is a multicenter, single-arm, open-label phase II study to evaluate the efficacy and safety of PM8002 in combination with chemotherapy in the first-line treatment of subjects with inoperable HCC.
- Trial name
- NCT05864105
- Testing
- PM8002, FOLFOX regimen
- Where
- 9 sites in China
- Volunteers
- 35 people
- Sponsor
- Biotheus Inc.
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
PH009-1 in Patients With EGFR Mutation Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
The study will contain three stages: Phase I includes dose escalation phase (i.e., phase Ia) and dose expansion phase (i.e., phase Ib).
- Trial name
- NCT06590194
- Testing
- PH009-1 tablet
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Suzhou Puhe Pharmaceutical Technology Co., LTD
RAS Mutation, Non-small Cell Lung Cancer (NSCLC)
This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation.
This is an open-label, multicenter Phase Ib/II clinical study evaluating GFH276 in combination with tislelizumab plus pemetrexed/platinum based regimen as first-line therapy in participants with locally advanced or metastatic…
- Trial name
- GFH276X1203 (NCT07846358)
- Testing
- GFH276, with or without Tislelizumab, Pemetrexed
- Volunteers
- 84 people
- Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
Non-muscle-invasive Bladder Cancer
T-Control® Safety for Cytostatics Management
The goal of this pilot clinical trial is to know if this study is feasable in terms of design, recruitment and interventions, as well as gather preliminary data to determine if the T-Control® catheter is safer than the…
- Trial name
- NCT06678633
- Testing
- T-Control® (experimental), Folysil® (control)
- Volunteers
- 16 people
- Sponsor
- Rethink Medical SL
Ovarian Neoplasms
CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy
The objective of this study is to compare the efficacy and safety of CAELYX versus Paclitaxel HCl in patients with epithelial ovarian carcinoma following failure of first-line, platinum-based chemotherapy.
- Trial name
- NCT00653952
- Testing
- CAELYX, Paclitaxel HCl
- Volunteers
- 220 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC
VERSATILE-002 is a Phase 2, open-label, multicenter study of the efficacy and safety of PDS0101 administered in combination with pembrolizumab in adults with HPV16 and PD-L1 positive recurrent or metastatic head and neck squamous…
- Conditions
- Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck
- Trial name
- VERSATILE002 (NCT04260126)
- Testing
- Pembrolizumab (KEYTRUDA®) and PDS0101
- Where
- 23 sites in United States, Ireland and 2 more
- Volunteers
- 95 people
- Sponsor
- PDS Biotechnology Corp.
Advanced Renal Cell Carcinoma
An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib For Treatment Of Patients With aRCC In The UK
An observational chart review study to describe the real-world outcomes and use of avelumab in combination with axitinib for treatment of patients with advanced renal cell carcinoma in the United Kingdom.
- Trial name
- NCT05394493
- Testing
- avelumab, axitinib
- Where
- United Kingdom
- Volunteers
- 130 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.